Scholarlink

Purpose <p>Urinary bladder cancer remains a significant global health challenge, with effective early preventive strategies urgently needed to reduce incidence and progression. This study explores the prophylactic potential of artemisinin against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced early-stage urothelial carcinoma in a mouse model.</p> Methods <p>A multidisciplinary approach was used to evaluate artemisinin’s molecular and physiological effects. Techniques included protein–protein interaction (PPI) network analysis, molecular docking, gene expression profiling, histopathological evaluation, and systemic biomarker assessment.</p> Results <p>PPI analysis revealed FGFR3, HRAS, and TP53 as central oncogenic drivers. Molecular docking confirmed strong binding affinities of artemisinin to these targets. Prophylactic artemisinin administration significantly downregulated FGFR3 and HRAS while upregulating TP53, indicating early correction of carcinogenic signaling. These molecular changes were associated with preserved bladder and renal histoarchitecture, normalized kidney function markers, and restored hematological profiles, reflecting systemic protection against BBN-induced toxicity.</p> Conclusions <p>Artemisinin effectively intercepts bladder carcinogenesis at multiple levels, modulating key genetic pathways and mitigating systemic damage. These findings provide compelling preclinical evidence supporting artemisinin as a promising prophylactic agent for bladder cancer prevention in high-risk populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月17日

查看全文
  • Silvia Botrous,
  • Ayaat Elmaghraby,
  • Samar El Achy,
  • Yehia Mustafa,
  • Salah Abdel-Rahman

摘要

Purpose

Urinary bladder cancer remains a significant global health challenge, with effective early preventive strategies urgently needed to reduce incidence and progression. This study explores the prophylactic potential of artemisinin against N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced early-stage urothelial carcinoma in a mouse model.

Methods

A multidisciplinary approach was used to evaluate artemisinin’s molecular and physiological effects. Techniques included protein–protein interaction (PPI) network analysis, molecular docking, gene expression profiling, histopathological evaluation, and systemic biomarker assessment.

Results

PPI analysis revealed FGFR3, HRAS, and TP53 as central oncogenic drivers. Molecular docking confirmed strong binding affinities of artemisinin to these targets. Prophylactic artemisinin administration significantly downregulated FGFR3 and HRAS while upregulating TP53, indicating early correction of carcinogenic signaling. These molecular changes were associated with preserved bladder and renal histoarchitecture, normalized kidney function markers, and restored hematological profiles, reflecting systemic protection against BBN-induced toxicity.

Conclusions

Artemisinin effectively intercepts bladder carcinogenesis at multiple levels, modulating key genetic pathways and mitigating systemic damage. These findings provide compelling preclinical evidence supporting artemisinin as a promising prophylactic agent for bladder cancer prevention in high-risk populations.